{"ticker": {"uuid": "5da254bc-b861-453c-8e74-b0adf19838bc", "symbol": "ONC", "name": "BeiGene, Ltd.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "ONC Stock Price and Chart \u2014 NASDAQ:ONC", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTFB2aUFXTVhxbDR6TjdFZVlpdy1ETkpqczgwRmI1QjV1NTNPRkI4OEZGOXJ6ekpDbTFfdGZ0LVQ5MVRza0xVSUVadzFmeEExNDY0d1V6QVhnMHhQU1lQMkoyQVkxNHg1bHJOUnMwQlZB?oc=5", "source_name": "TradingView", "published_at": "2026-07-21T09:10:56+00:00", "published_display": "21 Jul 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Given Consensus Rating of \"Moderate Buy\" by Brokerages", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOMzhCbm5COHRmZHl5dDd0dlZkOEM5YjZzZ1JlbGo4cmMzdnhMZnVpU3YydTJOSDNrVGhKV2hjRTBOOHJnaEwtWGpLOTd4d1pZNG9FS0FKeXB1bEhFOVJPZGZsczhLSVhrSjRhNzV6WGFjNTZZVmZBUWZZWldTeUdVTWN6ZE9aenp0Uk9HaVhaRHdUWmRzcVgyVkhrczFvbDZtVXFFeXU1dWcwTGJBUGRWZ2xoc09WVFBzdlZoMmJBYTRvNi1Wbm5YZjJoRXVEeDh3REhmZGoyR0JrbWdETElPaUFEc04?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-18T08:14:54+00:00", "published_display": "18 Jul 2026 08:14", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeOne Medicines (NASDAQ:ONC) Upgraded by Wall Street Zen to \"Strong-Buy\" Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQU053NURDeVJDRDVIZFZRNlUxMm0weXpXUjBoMXRxYk5nTHMtMlZqajJWcnd3bVYxWmhqUWlJOVRDSDBSN1ZCNUMwRG5zTmRFYzc0c0RDWVNWcklqRi1XTl9UZWU1WkdCaWRCSHJwdlRFay1FRmIwTTlEckhXMTd0dG5SdGtRcHF4cFFFRTFSbkpWcHlWY1RWVmdVd3FlMmZIVVI4aWt3VEVDR08yLVJ5RXpnOGhZcHAydnplVzRLcWRTUVlJRGdv?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-18T05:23:46+00:00", "published_display": "18 Jul 2026 05:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BeiGene(ONC.US) Officer Sells US$62.88 Million in Common Stock", "summary": "An officer at BeiGene (ONC.US) executed a sale of common stock totaling US$62.88 million. This transaction indicates a significant insider selling activity, which can be of interest to investors monitoring corporate governance and stock performance.", "url": "https://www.moomoo.com/news/post/72967423/beigene-oncus-officer-sells-us-62-88-million-in-common", "source_name": "Moomoo", "published_at": "2026-07-15T03:41:19", "published_display": "15 Jul 2026 03:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Jefferies Upgrades BeiGene(ONC.US) to Buy Rating, Raises Target Price to $380", "summary": "Jefferies has upgraded BeiGene (ONC.US) from a Hold to a Buy rating, concurrently increasing its target price to $380. This positive revision reflects a strong outlook for the biotechnology company.", "url": "https://www.moomoo.com/news/post/72816382/jefferies-upgrades-beigene-oncus-to-buy-rating-raises-target-price", "source_name": "Moomoo", "published_at": "2026-07-13T08:40:23", "published_display": "13 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Financial Maintains BeiGene(ONC.US) With Buy Rating, Announces Target Price $416", "summary": "Truist Financial has reiterated its Buy rating on BeiGene (ONC.US) and set a target price of $416 for the company's shares. This indicates a continued positive outlook from the firm regarding BeiGene's stock performance.", "url": "https://www.moomoo.com/news/post/72590334/truist-financial-maintains-beigene-oncus-with-buy-rating-announces-target", "source_name": "Moomoo", "published_at": "2026-07-07T19:14:05", "published_display": "07 Jul 2026 19:14", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Maintains BeiGene(ONC.US) With Buy Rating, Raises Target Price to $451", "summary": "RBC Capital analyst Leonid Timashev has maintained a Buy rating for BeiGene (ONC.US) and increased the target price from $436 to $451. The analyst has a notable success rate of 62.0% and an average return of 26.8% over the past year, according to TipRanks data. This adjustment re", "url": "https://www.moomoo.com/news/post/72586998/rbc-capital-maintains-beigene-oncus-with-buy-rating-raises-target", "source_name": "Moomoo", "published_at": "2026-07-07T14:40:20", "published_display": "07 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $340", "summary": "Wolfe Research has reiterated its Buy rating on BeiGene (BGNE.US) and maintained its target price of $340. The report reflects the firm's continued confidence in the pharmaceutical company's performance and future outlook.", "url": "https://www.moomoo.com/news/post/72399997/wolfe-research-maintains-beigene-oncus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-02T12:39:37", "published_display": "02 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $409", "summary": "Barclays has reiterated its Buy rating on BeiGene (ONC.US) and maintained a target price of $409. This continued endorsement suggests confidence in the company's future performance. The financial institution's updated rating provides insight into its current outlook on BeiGene's ", "url": "https://www.moomoo.com/news/post/71526108/barclays-maintains-beigene-oncus-with-buy-rating-maintains-target-price", "source_name": "Moomoo", "published_at": "2026-06-16T12:10:40", "published_display": "16 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $420", "summary": "Guggenheim has reiterated its Buy rating on BeiGene (ONC.US), maintaining a target price of $420. This indicates the firm's continued confidence in the pharmaceutical company's stock performance and future prospects.", "url": "https://www.moomoo.com/news/post/71533421/guggenheim-maintains-beigene-oncus-with-buy-rating-maintains-target-price", "source_name": "Moomoo", "published_at": "2026-06-15T23:39:47", "published_display": "15 Jun 2026 23:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "ONC Stock Price and Chart \u2014 NASDAQ:ONC", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTFB2aUFXTVhxbDR6TjdFZVlpdy1ETkpqczgwRmI1QjV1NTNPRkI4OEZGOXJ6ekpDbTFfdGZ0LVQ5MVRza0xVSUVadzFmeEExNDY0d1V6QVhnMHhQU1lQMkoyQVkxNHg1bHJOUnMwQlZB?oc=5", "source_name": "TradingView", "published_at": "2026-07-21T09:10:56+00:00", "published_display": "21 Jul 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Given Consensus Rating of \"Moderate Buy\" by Brokerages", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOMzhCbm5COHRmZHl5dDd0dlZkOEM5YjZzZ1JlbGo4cmMzdnhMZnVpU3YydTJOSDNrVGhKV2hjRTBOOHJnaEwtWGpLOTd4d1pZNG9FS0FKeXB1bEhFOVJPZGZsczhLSVhrSjRhNzV6WGFjNTZZVmZBUWZZWldTeUdVTWN6ZE9aenp0Uk9HaVhaRHdUWmRzcVgyVkhrczFvbDZtVXFFeXU1dWcwTGJBUGRWZ2xoc09WVFBzdlZoMmJBYTRvNi1Wbm5YZjJoRXVEeDh3REhmZGoyR0JrbWdETElPaUFEc04?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-18T08:14:54+00:00", "published_display": "18 Jul 2026 08:14", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeOne Medicines (NASDAQ:ONC) Upgraded by Wall Street Zen to \"Strong-Buy\" Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQU053NURDeVJDRDVIZFZRNlUxMm0weXpXUjBoMXRxYk5nTHMtMlZqajJWcnd3bVYxWmhqUWlJOVRDSDBSN1ZCNUMwRG5zTmRFYzc0c0RDWVNWcklqRi1XTl9UZWU1WkdCaWRCSHJwdlRFay1FRmIwTTlEckhXMTd0dG5SdGtRcHF4cFFFRTFSbkpWcHlWY1RWVmdVd3FlMmZIVVI4aWt3VEVDR08yLVJ5RXpnOGhZcHAydnplVzRLcWRTUVlJRGdv?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-18T05:23:46+00:00", "published_display": "18 Jul 2026 05:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeiGene(ONC.US) Officer Sells US$62.88 Million in Common Stock", "summary": "An officer at BeiGene (ONC.US) executed a sale of common stock totaling US$62.88 million. This transaction indicates a significant insider selling activity, which can be of interest to investors monitoring corporate governance and stock performance.", "url": "https://www.moomoo.com/news/post/72967423/beigene-oncus-officer-sells-us-62-88-million-in-common", "source_name": "Moomoo", "published_at": "2026-07-15T03:41:19", "published_display": "15 Jul 2026 03:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies Upgrades BeiGene(ONC.US) to Buy Rating, Raises Target Price to $380", "summary": "Jefferies has upgraded BeiGene (ONC.US) from a Hold to a Buy rating, concurrently increasing its target price to $380. This positive revision reflects a strong outlook for the biotechnology company.", "url": "https://www.moomoo.com/news/post/72816382/jefferies-upgrades-beigene-oncus-to-buy-rating-raises-target-price", "source_name": "Moomoo", "published_at": "2026-07-13T08:40:23", "published_display": "13 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Financial Maintains BeiGene(ONC.US) With Buy Rating, Announces Target Price $416", "summary": "Truist Financial has reiterated its Buy rating on BeiGene (ONC.US) and set a target price of $416 for the company's shares. This indicates a continued positive outlook from the firm regarding BeiGene's stock performance.", "url": "https://www.moomoo.com/news/post/72590334/truist-financial-maintains-beigene-oncus-with-buy-rating-announces-target", "source_name": "Moomoo", "published_at": "2026-07-07T19:14:05", "published_display": "07 Jul 2026 19:14", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Maintains BeiGene(ONC.US) With Buy Rating, Raises Target Price to $451", "summary": "RBC Capital analyst Leonid Timashev has maintained a Buy rating for BeiGene (ONC.US) and increased the target price from $436 to $451. The analyst has a notable success rate of 62.0% and an average return of 26.8% over the past year, according to TipRanks data. This adjustment re", "url": "https://www.moomoo.com/news/post/72586998/rbc-capital-maintains-beigene-oncus-with-buy-rating-raises-target", "source_name": "Moomoo", "published_at": "2026-07-07T14:40:20", "published_display": "07 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $340", "summary": "Wolfe Research has reiterated its Buy rating on BeiGene (BGNE.US) and maintained its target price of $340. The report reflects the firm's continued confidence in the pharmaceutical company's performance and future outlook.", "url": "https://www.moomoo.com/news/post/72399997/wolfe-research-maintains-beigene-oncus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-02T12:39:37", "published_display": "02 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $409", "summary": "Barclays has reiterated its Buy rating on BeiGene (ONC.US) and maintained a target price of $409. This continued endorsement suggests confidence in the company's future performance. The financial institution's updated rating provides insight into its current outlook on BeiGene's ", "url": "https://www.moomoo.com/news/post/71526108/barclays-maintains-beigene-oncus-with-buy-rating-maintains-target-price", "source_name": "Moomoo", "published_at": "2026-06-16T12:10:40", "published_display": "16 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $420", "summary": "Guggenheim has reiterated its Buy rating on BeiGene (ONC.US), maintaining a target price of $420. This indicates the firm's continued confidence in the pharmaceutical company's stock performance and future prospects.", "url": "https://www.moomoo.com/news/post/71533421/guggenheim-maintains-beigene-oncus-with-buy-rating-maintains-target-price", "source_name": "Moomoo", "published_at": "2026-06-15T23:39:47", "published_display": "15 Jun 2026 23:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 111, "total_relevant": 19, "sentiment_summary": {"positive": 8, "negative": 2, "neutral": 9, "score": 59, "total": 19, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "analyst", "primary_label": "Analyst action", "confidence": 77, "events": [{"event": "analyst", "label": "Analyst action", "weight": 4.4, "count": 8}, {"event": "earnings", "label": "Earnings", "weight": 3.71, "count": 9}, {"event": "general", "label": "Market update", "weight": 1.1, "count": 2}], "positive_events": 8, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 312.02, "latest_week": "2026-07-17", "one_week_move": 4.5, "four_week_move": 15.5, "twelve_week_move": 3.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.285549, "market_dynamics_buy_signal": false, "relative_strength": -11.098362, "fair_value_gap": 32.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 50.4229, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+4.5% over one week, +15.5% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 68, "badges": [], "opportunities": [], "risks": [], "event_label": "Analyst action", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Moomoo", "count": 7}, {"label": "Market source", "count": 6}, {"label": "TradingView", "count": 2}, {"label": "MarketBeat", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 10}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 9}, {"label": "Analyst action", "count": 8}, {"label": "Market update", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Analyst action", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "10", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+4.5% over one week, +15.5% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "ONC Stock Price and Chart \u2014 NASDAQ:ONC"}], "updated_at": "2026-07-21T21:22:14.029781+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}